Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
Yehuda Carmeli(Israel Ministry of Health), Surbhi Malhotra‐Kumar(University of Antwerp), Herman Goossens(Antwerp University Hospital), Joseph W. Chow(Pfizer (United States)), Illia Gumenchuk(Kyiv City Clinical Oncology Center), Rienk Pypstra(Pfizer (United States)), Minggui Wang(Fudan University), Francis F. Arhin(Pfizer (Canada)), George L. Daikos(National and Kapodistrian University of Athens), Julián Torre‐Cisneros(Instituto de Salud Carlos III), Joanne L. Leaney(Pfizer (United Kingdom)), O. V. Pyptіuk(Ivano-Frankivsk National Medical University), Jesús Rodríguez‐Baño(Hospital Universitario Virgen Macarena), Firdevs Aksoy(Karadeniz Technical University), Mical Paul(Rabin Medical Center), Michele Wible, Gang Chen(Tongji Hospital), Yongjie Zhao(Tianjin People's Hospital), Lu Liang(Baotou Central Hospital), Halley Rogers(Pfizer (United States)), Ivan Titov(Ivano-Frankivsk National Medical University), Alison Luckey(Global Antibiotic Research & Development Partnership), Christine Lammens, R. Jiménez-Rodríguez(Hospital Universitario Virgen del Rocío), George Singer(UCLA Medical Center), Marc Bonten, José Miguel Cisneros(Hospital Universitario Virgen del Rocío)
Cited by 98
Related Papers
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
|The Lancet|2005|3.1k
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
|The Lancet|2005|1.4k
Anidulafungin versus Fluconazole for Invasive Candidiasis
|New England Journal of Medicine|2007|896
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
|Clinical Microbiology Reviews|2018|688